DVAX — Dynavax Technologies Corporation

Summary of Dynavax Technologies Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Net Product Revenue: $90 million from HEPLISAV-B, a 13% increase year-over-year.
• Total Revenue: Approximately $95 million, up 18% year-over-year.
• Gross Margin: HEPLISAV-B gross margin at 84%.
• GAAP Net Income: $27 million, compared to $18 million in Q3 2024.
• Non-GAAP Adjusted EBITDA: Improved to $36 million from $25 million year-over-year.
• Cash Position: $648 million at the end of Q3, down from $714 million at the end of 2024, primarily due to share repurchase activities.

2. Strategic Updates and Business Highlights:

• HEPLISAV-B: Continued strong performance with a market share increase to 46% (up from 44% year-over-year), with retail segment share growing to 63%.
• Pipeline Advancements: Progress in shingles vaccine (Z-1018) with initiation of Part 2 of Phase I/II study, and additional funding for plague vaccine from the Department of Defense.
• COVID-19 Vaccine License Agreement: Exclusive license for Vaxart's oral COVID-19 vaccine program, which is in Phase IIb trials. Dynavax has the option to opt into development based on Phase IIb data expected in late 2026.
• Share Repurchase Program: New authorization for a $100 million share repurchase plan, reflecting confidence in long-term growth.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: HEPLISAV-B net product revenue expected to be between $315 million and $325 million, with adjusted EBITDA projected to be at least $80 million, up from previous guidance of $75 million.
• Long-Term Market Share Goal: Targeting at least 60% market share for HEPLISAV-B by 2030, supported by ongoing growth in the retail segment and strategic marketing efforts.

4. Bad News, Challenges, or Points of Concern:

• Seasonality Impact: Anticipated revenue decline in Q4 due to seasonal factors, particularly holiday-related slowdowns.
• Market Competition: Concerns regarding the competitive landscape for COVID-19 vaccines and the need for differentiation in efficacy and delivery methods.
• Development Risks: Potential challenges related to the Vaxart COVID-19 vaccine program, including uncertainties surrounding regulatory feedback and the efficacy of the oral vaccine compared to existing mRNA options.

5. Notable Q&A Insights:

• COVID Vaccine Licensing: CEO Ryan Spencer emphasized the strategic timing for licensing the oral COVID-19 vaccine, highlighting the potential for market growth through improved delivery mechanisms and efficacy.
• Study Size Concerns: Addressed questions regarding the reduced enrollment in the Vaxart trial, asserting that the current size is sufficient to demonstrate efficacy.
• Development Capacity: Spencer confirmed that Dynavax is positioned to manage simultaneous registrational studies for both the shingles vaccine and the oral COVID-19 vaccine if both programs advance successfully.
• Market Share Confidence: Management expressed confidence in achieving long-term market share goals, citing ongoing growth in retail and institutional segments.

This summary encapsulates the key elements from the earnings call, highlighting Dynavax's financial performance, strategic initiatives, future outlook, and potential challenges.